ELIGIBILITY:

- **Biomarkers:**
  - Proinflammatory Panel 1 by Mesoscale Discovery (MSD) platform for multiplexed cytokine analyses

- **Disease Control Rate (DCR):**

- **Intention to treat population (ITT):** all enrolled
- **Efficacy evaluable population (EE):** received 3 doses and scans

PART 2: randomization to ICT01 7 mg or 200 mg IV Q3W + PEM 200 mg

- **Group C:** disease progression, failed to undergo biopsies

WILLINGNESS

Efficacy assessment by RECIST 1.1 Q8W:

- **ICT01-modulated γ9δ2 T cells:** increase surface expression of PD-1 in vitro and in vivo in 3B. Treatment-related AE per severity

Table 1: Prior lines of therapy

<table>
<thead>
<tr>
<th>Line of Treatment</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10 (100)</td>
</tr>
<tr>
<td>2</td>
<td>34 (80)</td>
</tr>
<tr>
<td>≥1 checkpoint inhibitor (CPI)</td>
<td>10 (100)</td>
</tr>
</tbody>
</table>

85% of patients are ≥1 CPI.

CONCLUSIONS

- **ICT01 in combination with PEM has a manageable safety profile.**
- **ICT01 in combination with PEM demonstrates efficacy in 2L CPI refractory melanoma patients warranting further investigation.**
- **DCR is related to baseline BNT3A expression, sustained elevation of IFNγ levels, and expression markers of tumor microenvironment remodeling.**
- **Patient selection based on BNT3A tumor expression will be further evaluated as a potential enrichment strategy.**